Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Is Sorafenib beneficial in patients with post-transplant hepatocellular carcinoma recurrence.

Trial Profile

Is Sorafenib beneficial in patients with post-transplant hepatocellular carcinoma recurrence.

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Nov 2018

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Nov 2018 New trial record
    • 05 Nov 2018 Primary endpoint (efficacy of sorafenib in patients with no otherwise treatable Hepatocellular carcinoma recurrence after Liver transplant compared to best supportive care, according to survival time) has been met as per results published in the Journal of Korean Medical Science
    • 05 Nov 2018 Results published in the Journal of Korean Medical Science
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top